| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5538 | wrr-483 | Analog of K11777; Irriversible effective cysteine protease inhibitor with trypanocidal activity in cell culture and animal model with comparable efficacy to K11777. |
|
| DCC5539 | Ws-47-js03 | Novel potent RET kinase inhibitor with >500-fold selectivity against KDR (Kinase insert Domain Receptor) in cellular assays |
|
| DCC5540 | Ws-691 | Novel highly potent and orally active ABCB1 modulator capable of overcoming MDR, stabilizing ABCB1 by directly binding to ABCB1, stimulating the activity of ABCB1 ATPase without inhibitory activity against CYP3A4, increasing the sensitivity of SW620/Ad300 |
|
| DCC5541 | Wsj-557 | Novel xanthine oxidase inhibitor |
|
| DCC5542 | Wu-07047 | Simplified analog of the selective Gαq/11 inhibitor YM-25489 |
|
| DCC5543 | Wwl123 | Novel α/ß-hydrolase domain 6 (ABHD6) inhibitor |
|
| DCC5544 | Wx-671 | Novel urokinase inhibitor |
|
| DCC5545 | Wye-687 Dihydrochloride | Potent, ATP-competitive inhibitor of mammalian target of rapamycin (mTOR) |
|
| DCC5546 | Wyk431 | Potent inhibitor of proliferation activity against a broad spectrum of human cancer cell lines, induces G2/M phase arrest and apoptosis through the PI3K/Akt pathway |
|
| DCC5547 | Xanthoangelol | Natural antibacterial agent against Gram-positive bacterial pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus faecium and Enterococcus faecalis |
|
| DCC5548 | Xantholipin | Antibiotic, exhibiting strong antibacterial activities and showing potent cytotoxicity, inhibiting HSP47 gene expression produced by Streptomyces sp |
|
| DCC5549 | Xantholipin B | Novel antibiotic, showing 3- to 10-fold greater cytotoxicity than Xantholipin against a select panel of human cancer cell lines, demonstrating powerful antimicrobial activity against both Gram-positive bacteria and fungi |
|
| DCC5550 | XAX-162 | Quantity (mg or Unit) Unit Price ($/mg or $/Unit) Final Price 100 $26.55 Total: $2,655.00 50 $30.68 Total: $1,534.00 25 $35.99 Total: $899.75 10 $42.48 Total: $424.80 5 $50.15 Total: $250.75 |
|
| DCC5551 | xc-409 | Novel PKM2 activator |
|
| DCC5552 | Xen103 | Potent and Selective Stearoyl-CoA Desaturase-1 Inhibitor |
|
| DCC5553 | Xie18-6 | Novel INK4C inhibitor, specifically blocking the bioactivity of p18 protein and promoting human and murine hematopoietic stem cell ex vivo expansion |
|
| DCC5554 | Xist Ligand X1 | Novel non-coding RNA prototype Xist ligand, specifically binding the RepA motif of Xist, reducing the conformational space of RepA, displacing cognate interacting protein factors (PRC2 and SPEN), suppressing histone H3K27 trimethylation, and blocking init |
|
| DCC5555 | Xl-13n | Novel dual inhibitor of AF9 and ENL YEATS domains |
|
| DCC5556 | Xl-147 | Novel Potent Pan-Filovirus Inhibitor, showing potent inhibition against infectious EBOV Zaire (0.09 μM) and MARV (0.64 μM) |
|
| DCC5557 | Xl-418 | Novel Akt1/2 inhibitor |
|
| DCC5558 | Xr9051 Hydrochloride | Potent modulator of P-glycoprotein-mediated multidrug resistance (MDR), inhibiting the binding of cytotoxics to P-glycoprotein |
|
| DCC5559 | Xstax-vhll | Novel selective β-catenin degrader |
|
| DCC5560 | Xylariamide A | Carbonic anhydrase inhibitor; Fungal metabolite |
|
| DCC5561 | Xylarianaphthol-1 | Novel activator of p21 promoter in a p53-independent manner |
|
| DCC5562 | Y08624 | Novel TRIM24/BRPF1 dual inhibitor with IC 50 values of 0.98 and 1.16 μM, respectively |
|
| DCC5563 | Y2 Antagonist 36 | Novel non-peptidic highly potent, soluble and selective NPY Y2 antagonist |
|
| DCC5564 | Y2-antagonist-2 | Novel, selective, soluble non-peptidic NPY Y2 receptor antagonist with enhanced CNS exposure |
|
| DCC5565 | Y-39983 Dihydrochloride | Selective Rho-associated kinase (ROCK) inhibitor |
|
| DCC5566 | Yak037 | Tamoxifen-analog that Suppresses Glial L-Glutamate Transport Activity without Interaction with Estrogen_receptor>Estrogen Receptors |
|
| DCC5567 | Ycw-e11 | Novel Inhibitor of Antiapoptotic Bcl-2 Family Proteins |
|
